Bit Capital Gmb H Crinetics Pharmaceuticals, Inc. Transaction History

Bit Capital Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2025	SELL	$25.62 - $37.07 $591,360 - $855,649	-23,082 Closed	0 $0
Q3 2023 Feb 12, 2025	SELL	$15.97 - $30.59 $355,763 - $681,453	-22,277 Reduced 49.11%	23,082 $686 Million
Q2 2023 Feb 12, 2025	BUY	$15.73 - $23.6 $83,321 - $125,009	5,297 Added 13.22%	45,359 $817 Million
Q1 2023 Feb 12, 2025	BUY	$15.31 - $21.1 $274,431 - $378,217	17,925 Added 80.97%	40,062 $643 Million
Q4 2022 Feb 12, 2025	SELL	$15.49 - $19.05 $124,679 - $153,333	-8,049 Reduced 26.66%	22,137 $405 Million
Q3 2022 Feb 12, 2025	BUY	$18.11 - $22.37 $374,623 - $462,745	20,686 Added 217.75%	30,186 $593 Million
Q1 2022 Feb 12, 2025	BUY	$17.15 - $28.31 $162,925 - $268,945	9,500 New	9,500 $209 Million

251

83.3M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.89B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

Stay updated on Bit Capital Gmb H with notifications on news.